Dynavax Technologies (DVAX) Q2 2024 earnings summary

Executive summary

• Achieved record HEPLISAV-B net product revenue of $70.2M in Q2 2024, up 24% year-over-year, with U.S. market share rising to ~42% and strong gains in retail and IDN segments.

• Net income reached $11.4M in Q2 2024, up from $3.4M in Q2 2023, reversing prior losses.

• Advanced clinical pipeline with new trials for shingles (Z-1018), Tdap, and plague vaccines, with key milestones expected through 2025.

• Maintained robust capital position with $735.6M in cash, cash equivalents, and marketable securities as of June 30, 2024.

• Reaffirmed full-year 2024 HEPLISAV-B net product revenue guidance of $265–$280M.

Financial highlights

• Q2 2024 total revenues reached $73.8M, a 22% year-over-year increase; HEPLISAV-B net product revenue was $70.2M.

• Net income for Q2 2024 was $11.4M ($0.09 basic, $0.08 diluted EPS), up from $3.4M ($0.03 EPS) in Q2 2023.

• Gross margin for HEPLISAV-B improved to approximately 80%–83% in Q2 2024.

• Cost of sales for HEPLISAV-B decreased 11% year-over-year, reflecting lower per-unit manufacturing costs.

• R&D expenses were $15M and SG&A expenses were $41.7M in Q2 2024.

Outlook and guidance

• Reaffirmed full-year 2024 HEPLISAV-B net product revenue guidance of $265–$280M.

• R&D expenses forecasted at $60–$75M and SG&A at $160–$180M for 2024.

• Cash and marketable securities expected to increase by year-end 2024, supporting operations for at least the next 12 months.

• Minimal to no CpG 1018 adjuvant revenue expected for the remainder of 2024.

• HEPLISAV-B market opportunity projected to exceed $800M by 2027, with majority market share anticipated.